Synthesis: Radiation therapy in TNBC

Evidence grades (GRADE-adapted): A high — multiple well-conducted RCTs or systematic reviews converge. B moderate — single pivotal RCT or consistent observational evidence. C limited — single observational study, mechanistic, or expert consensus. D preclinical / hypothesis-generating.

Where radiation fits in TNBC management

Radiation therapy in TNBC is given for two principal indications:

• After breast-conserving surgery (lumpectomy) — whole-breast radiation is essentially always given to reduce local recurrence risk. The Cochrane meta-analysis and EBCTCG individual-patient-data analyses confirm radiation reduces local recurrence by ~50% across breast cancer subtypes including TNBC, with a corresponding reduction in long-term breast-cancer mortality.
• After mastectomy — post-mastectomy radiation (PMRT) is given for higher-risk disease (positive margins, multiple positive nodes, large tumor size, locally advanced features). The decision is more nuanced and varies by surgical and clinical risk factors.

Regional nodal radiation (axillary, supraclavicular) is added when lymph-node involvement is present or when the patient meets specific high-risk criteria, again following breast-cancer-general principles rather than TNBC-specific guidance.

Hypofractionation: modern dose-fractionation evidence

Conventionally, post-lumpectomy whole-breast radiation was delivered as 1.8–2 Gy daily fractions over 5–6 weeks (total ~50 Gy). Multiple randomized trials over the past 20 years have established that shorter, higher-per-fraction-dose schedules produce equivalent outcomes with less patient burden.

START-A and START-B

The UK START trials randomized 4,451 patients (across the two arms) to 50 Gy in 25 fractions over 5 weeks (standard) vs hypofractionated schedules: START-A used 41.6 Gy or 39 Gy in 13 fractions over 5 weeks; START-B used 40 Gy in 15 fractions over 3 weeks^[1]A. Both hypofractionation arms produced equivalent or non-inferior local control compared with standard fractionation, with similar or improved late-toxicity profiles.

Whelan 2010 (Canadian trial)

Whelan and colleagues randomized 1,234 women to 42.5 Gy in 16 fractions over 22 days vs the standard 50 Gy in 25 fractions^[2]A. At 12-year follow-up, local recurrence rates were equivalent (6.7% hypofractionation vs 6.2% standard) with similar cosmetic outcomes.

FAST-Forward

Brunt and colleagues randomized 4,096 women to 26 Gy in 5 fractions over 1 week vs 40 Gy in 15 fractions over 3 weeks (the now-standard hypofractionation)^[3]A. The 5-year ipsilateral breast-tumor relapse rate was 2.2% with 5-fraction vs 2.1% with 15-fraction (non-inferior). Late normal tissue effects (breast appearance, induration, edema) were similar between arms. The 5-fraction regimen is now widely adopted in the UK and increasingly used in the US for selected lower-risk patients.

What this means for TNBC

None of the hypofractionation trials were TNBC-specific, but TNBC was represented within each trial's population. Subgroup analyses by ER status (within START-A/B and Whelan 2010) did not show subtype-specific differences in efficacy or toxicity outcomes, supporting application of hypofractionation across breast cancer subtypes including TNBC. NCCN and ESMO guidelines support hypofractionation as the preferred standard for most TNBC patients after breast-conserving surgery.

Post-mastectomy radiation in TNBC

Post-mastectomy radiation therapy (PMRT) reduces local-regional recurrence in higher-risk patients. The decision is informed by:

• Number of positive axillary lymph nodes. 4+ positive nodes: PMRT is essentially always given. 1–3 positive nodes: decision is patient-specific, considering other risk factors. Node-negative: PMRT generally omitted unless other high-risk features.
• Tumor size and locally advanced features. pT3 or pT4 disease, inflammatory disease, or skin/chest-wall involvement strongly favor PMRT.
• Margin status. Positive surgical margins favor PMRT (though re-excision is usually attempted first).
• Patient age and life expectancy. Younger patients with longer expected post-cancer life benefit more from local-regional control.

For TNBC specifically, the chemotherapy responsiveness and biology of recurrence patterns suggest that PMRT may be especially valuable in high-risk patients — TNBC has higher local-regional recurrence risk than HR+ disease at any given pathologic stage, so the absolute benefit of PMRT is larger.

Radiation timing in the KEYNOTE-522 era

The standard sequence in TNBC patients receiving KEYNOTE-522:

1. Neoadjuvant pembrolizumab + chemotherapy (24 weeks)
2. Surgery (typically 2–6 weeks after last neoadjuvant dose)
3. Adjuvant pembrolizumab continuation (~27 weeks)
4. Adjuvant chemotherapy (capecitabine, olaparib, etc.) if applicable
5. Radiation therapy — concurrent with or after the adjuvant systemic therapy

An operational question is whether radiation should be given concurrently with adjuvant pembrolizumab, before, or after. Most centers give radiation concurrently with adjuvant pembrolizumab, recognizing that the immune-modulatory effects of radiation may complement IO benefit but that toxicity (skin reactions, fatigue) may be additive. Limited prospective safety data inform this practice; published case series and retrospective cohorts report manageable toxicity.

Pneumonitis risk — a small concern with both pembrolizumab and chest-wall radiation — warrants attention in patients receiving both, particularly with internal mammary nodal radiation that may include lung volume in the radiation field.

Emerging radiation de-escalation questions

Several trials and registries are testing whether radiation can be omitted in low-risk TNBC subsets:

• Older patients (typically > 70). Hughes 2013 (CALGB 9343) showed equivalent overall survival with vs without radiation after lumpectomy in older HR+ patients, with the local-recurrence trade-off accepted in clinical decision-making. Whether analogous trials in older TNBC patients could justify radiation omission is being considered; the higher local-recurrence rate in TNBC makes the trade-off less favorable.
• Very-high-TIL TNBC. The hypothesis that high-TIL TNBC has favorable enough local control with chemotherapy + IO alone to permit radiation de-escalation is being tested. Preliminary retrospective data suggest local recurrence rates in high-TIL pCR achievers are very low.
• Partial-breast radiation — treating only the lumpectomy bed and a margin rather than the whole breast. APBI techniques (intra-operative radiation, brachytherapy, or external-beam partial-breast plans) reduce treatment volume and toxicity. NSABP B-39 and similar trials inform breast-cancer-general use; TNBC-specific data are within those broader datasets.

Cardiac considerations in TNBC radiation

Left-sided breast radiation can expose part of the heart to substantial dose, with documented long-term cardiac-mortality consequences in older cohorts treated before modern technique. Modern radiation planning (deep-inspiration breath-hold, prone positioning, intensity-modulated radiation, proton therapy in selected cases) substantially reduces cardiac dose. Most published cardiac-toxicity data come from cohorts of HR+ breast cancer; TNBC patients tend to be younger and may have longer post-cancer life expectancy, making cardiac sparing especially important.

Evidence table

Open questions and active investigation

• Radiation omission in pCR-achieving very-high-TIL TNBC. Whether complete pathologic response in immune-rich TNBC permits safe radiation omission is being studied prospectively. The hypothesis: if chemotherapy + IO eradicated the tumor completely and the underlying immune biology is favorable, the residual recurrence risk is so low that radiation toxicity outweighs benefit.
• Optimal sequencing with adjuvant pembrolizumab. Concurrent radiation + pembrolizumab is current practice but limited prospective safety data exist. Trials with formal safety endpoints would resolve operational uncertainty.
• Hypofractionation for regional nodal radiation. Most hypofractionation evidence is for whole-breast radiation; regional nodal radiation has been studied less extensively in TNBC-specific cohorts. RTOG 1304 and similar trials are filling this gap.
• Proton therapy for selected TNBC patients. Cardiac sparing may justify proton therapy in younger left-sided TNBC patients with anatomically unfavorable internal mammary node radiation; randomized comparison with intensity-modulated photon therapy is the RADCOMP trial.
• Radiation + IO synergy mechanism. Preclinical evidence suggests radiation can convert immunologically cold tumors to inflamed ones, potentially augmenting IO benefit. Whether this translates into clinically meaningful synergy in TNBC is being tested with abscopal-effect strategies in metastatic disease.
• Late effects monitoring in long-term TNBC survivors. As TNBC patients live longer due to KEYNOTE-522-era improvements, the long-term radiation late effects (cardiac, secondary cancers, fibrosis) become more clinically relevant. Long-term follow-up cohorts are needed.

For the neoadjuvant regimen that radiation follows, see the KEYNOTE-522 synthesis. For surgical decision-making, see the (forthcoming) surgical considerations synthesis. For long-term toxicities including cardiac effects, see the (forthcoming) long-term toxicities synthesis.

References

Each citation links to the original publication via DOI. The same records are searchable in the evidence library by title or DOI.

1. START Trialists' Group, Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098–1107. doi:10.1016/S0140-6736(08)60348-7. ↩
2. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–520. doi:10.1056/NEJMoa0906260. ↩
3. Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward). Lancet. 2020;395(10237):1613–1626. doi:10.1016/S0140-6736(20)30932-6. ↩
4. Early Breast Cancer Trialists' Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–1716. doi:10.1016/S0140-6736(11)61629-2. ↩
5. Early Breast Cancer Trialists' Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–2135. doi:10.1016/S0140-6736(14)60488-8. ↩

Last reviewed: 2026-06-04. Researcher-layer synthesis page. Evidence grades follow the GRADE-adapted rubric defined at the top of this page.